1. Home
  2. NKTR vs SERA Comparison

NKTR vs SERA Comparison

Compare NKTR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • SERA
  • Stock Information
  • Founded
  • NKTR 1990
  • SERA 2008
  • Country
  • NKTR United States
  • SERA United States
  • Employees
  • NKTR N/A
  • SERA N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • SERA Precision Instruments
  • Sector
  • NKTR Health Care
  • SERA Health Care
  • Exchange
  • NKTR Nasdaq
  • SERA Nasdaq
  • Market Cap
  • NKTR 247.9M
  • SERA 208.7M
  • IPO Year
  • NKTR 1994
  • SERA 2021
  • Fundamental
  • Price
  • NKTR $0.90
  • SERA $6.64
  • Analyst Decision
  • NKTR Strong Buy
  • SERA
  • Analyst Count
  • NKTR 5
  • SERA 0
  • Target Price
  • NKTR $4.50
  • SERA N/A
  • AVG Volume (30 Days)
  • NKTR 1.5M
  • SERA 153.6K
  • Earning Date
  • NKTR 03-03-2025
  • SERA 03-19-2025
  • Dividend Yield
  • NKTR N/A
  • SERA N/A
  • EPS Growth
  • NKTR N/A
  • SERA N/A
  • EPS
  • NKTR N/A
  • SERA N/A
  • Revenue
  • NKTR $93,137,000.00
  • SERA $94,000.00
  • Revenue This Year
  • NKTR $12.85
  • SERA N/A
  • Revenue Next Year
  • NKTR N/A
  • SERA $4,263.64
  • P/E Ratio
  • NKTR N/A
  • SERA N/A
  • Revenue Growth
  • NKTR 5.53
  • SERA N/A
  • 52 Week Low
  • NKTR $0.50
  • SERA $4.98
  • 52 Week High
  • NKTR $1.93
  • SERA $12.36
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 40.16
  • SERA 40.96
  • Support Level
  • NKTR $0.87
  • SERA $6.03
  • Resistance Level
  • NKTR $0.94
  • SERA $6.83
  • Average True Range (ATR)
  • NKTR 0.09
  • SERA 0.59
  • MACD
  • NKTR -0.01
  • SERA -0.19
  • Stochastic Oscillator
  • NKTR 15.63
  • SERA 22.59

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Share on Social Networks: